Lazard Asset Management LLC Invests $82,000 in Adicet Bio, Inc. (NASDAQ:ACET)

Lazard Asset Management LLC bought a new position in Adicet Bio, Inc. (NASDAQ:ACETGet Rating) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 5,669 shares of the company’s stock, valued at approximately $82,000.

A number of other hedge funds have also recently modified their holdings of the stock. Cowen AND Company LLC boosted its stake in shares of Adicet Bio by 62.9% in the second quarter. Cowen AND Company LLC now owns 2,443,780 shares of the company’s stock worth $35,679,000 after buying an additional 943,725 shares during the last quarter. Jackson Creek Investment Advisors LLC acquired a new position in Adicet Bio in the 2nd quarter worth about $919,000. Candriam S.C.A. acquired a new position in Adicet Bio in the 2nd quarter worth about $18,740,000. Victory Capital Management Inc. acquired a new position in Adicet Bio in the 2nd quarter worth about $337,000. Finally, SG Americas Securities LLC acquired a new position in Adicet Bio in the 2nd quarter worth about $160,000.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the company. Truist Financial reduced their price target on Adicet Bio to $27.00 in a report on Tuesday, August 23rd. Wedbush upped their price target on Adicet Bio to $30.00 in a report on Wednesday, November 16th. JPMorgan Chase & Co. assumed coverage on Adicet Bio in a report on Wednesday, September 21st. They issued an “overweight” rating and a $23.00 price target for the company. Finally, StockNews.com initiated coverage on Adicet Bio in a report on Wednesday, October 12th. They issued a “sell” rating for the company. One research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $27.75.

Insider Activity at Adicet Bio

In related news, CEO Chen Schor sold 66,947 shares of the stock in a transaction that occurred on Monday, September 12th. The stock was sold at an average price of $16.77, for a total value of $1,122,701.19. Following the completion of the sale, the chief executive officer now owns 122,712 shares of the company’s stock, valued at $2,057,880.24. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, CEO Chen Schor sold 66,947 shares of the stock in a transaction that occurred on Monday, September 12th. The stock was sold at an average price of $16.77, for a total value of $1,122,701.19. Following the completion of the sale, the chief executive officer now owns 122,712 shares of the company’s stock, valued at $2,057,880.24. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Blake Aftab sold 1,646 shares of the stock in a transaction that occurred on Wednesday, October 12th. The shares were sold at an average price of $15.40, for a total value of $25,348.40. Following the completion of the sale, the insider now directly owns 51,176 shares of the company’s stock, valued at approximately $788,110.40. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 103,128 shares of company stock valued at $1,794,728. 29.20% of the stock is currently owned by insiders.

Adicet Bio Price Performance

Shares of Adicet Bio stock opened at $17.20 on Thursday. The business has a 50 day simple moving average of $16.54 and a two-hundred day simple moving average of $15.10. Adicet Bio, Inc. has a 12 month low of $9.29 and a 12 month high of $21.87. The stock has a market capitalization of $737.04 million, a P/E ratio of -12.13 and a beta of 2.14.

Adicet Bio Profile

(Get Rating)

Adicet Bio, Inc, a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients.

See Also

Want to see what other hedge funds are holding ACET? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Adicet Bio, Inc. (NASDAQ:ACETGet Rating).

Institutional Ownership by Quarter for Adicet Bio (NASDAQ:ACET)

Receive News & Ratings for Adicet Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adicet Bio and related companies with MarketBeat.com's FREE daily email newsletter.